Share on Facebook
Share on Twitter
Share on LinkedIn

The Food and Drug Administration, signaling stepped-up concerns about unapproved stem-cell treatments, on Thursday warned a California manufacturer about marketing “dangerous” products linked to serious infections in several patients.

The agency sent the warning letter to San Diego-based Genetech Inc., which sold cellular treatments derived from umbilical cord blood to Liveyon LLC, a distributor based in Irvine, Calif. The FDA said 12 patients who received the treatments subsequently became ill from blood and other infections caused by bacteria, including E. coli.

Read More